A post-hoc analysis [50] of pooled data from the two Leuven studies [45, 46] further confirmed that TGC carried a significantly higher risk of hypoglycemia (which occurred in 11.3% of patients on TGC vs. 1.8% of those on conventional insulin therapy, p < 0.0001). The gene discussed is INS; the disease is Hypoglycemia.